Trial · NCT02964507
Adverse event totals24
The totals the trial posted for each group.
1 to 20 of 24
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phase I- GSK525762 60mg+FUL 500mg (AI Failure) | 11 | 33 |
| Total, all-cause mortality | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure < 12M) | 9 | 12 |
| Total, all-cause mortality | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M) | 12 | 42 |
| Total, all-cause mortality | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M Bone Only Disease | 2 | 7 |
| Total, all-cause mortality | Phase I-GSK525762 80mg+FUL 500mg (AI Failure) | 10 | 18 |
| Total, all-cause mortality | Phase I-GSK525762 80mg+FUL 500mg (CDK4/6+AI Failure) | 5 | 11 |
| Total, all-cause mortality | Phase II-GSK525762 +FUL | 0 | 0 |
| Total, all-cause mortality | Phase II-Placebo+FUL | 0 | 0 |
| Total, other adverse events | Phase I- GSK525762 60mg+FUL 500mg (AI Failure) | 33 | 33 |
| Total, other adverse events | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure < 12M) | 12 | 12 |
| Total, other adverse events | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M) | 42 | 42 |
| Total, other adverse events | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M Bone Only Disease | 7 | 7 |
| Total, other adverse events | Phase I-GSK525762 80mg+FUL 500mg (AI Failure) | 18 | 18 |
| Total, other adverse events | Phase I-GSK525762 80mg+FUL 500mg (CDK4/6+AI Failure) | 11 | 11 |
| Total, other adverse events | Phase II-GSK525762 +FUL | 0 | 0 |
| Total, other adverse events | Phase II-Placebo+FUL | 0 | 0 |
| Total, serious adverse events | Phase I- GSK525762 60mg+FUL 500mg (AI Failure) | 5 | 33 |
| Total, serious adverse events | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure < 12M) | 1 | 12 |
| Total, serious adverse events | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M) | 10 | 42 |
| Total, serious adverse events | Phase I-GSK525762 60mg+FUL 500mg (CDK4/6+AI Failure >=12M Bone Only Disease | 3 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02964507/event-totals